Neuronetics Inc Dossier - Source-backed chat

Neuronetics Inc

STIMNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.06

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $2.22Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $169.2M

Enterprise Value $211.5M

Shares Outstanding 73.5M diluted

Next Earnings Date3 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Neuronetics, Inc. (NASDAQ: STIM) is a commercial-stage medical technology company leading the transcranial magnetic stimulation (TMS) market with its NeuroStar Advanced Therapy system. The strategic acquisition of Greenbrook TMS has significantly scaled the company's top-line revenue, transforming it into a vertically integrated provider of both medical devices and clinical services. However, this business mix shift has severely pressured gross margins, which fell from historical levels above 70% to under 50%. While Q1 2026 results demonstrated solid revenue growth of 8% year-over-year and narrowing net losses, the company remains unprofitable and is projected to generate negative operating cash flow of $13 million to $17 million for the full year 2026. Given the execution risks associated with the Greenbrook integration, margin dilution, and a tight cash runway ($19.0 million as of March 31, 2026), a Hold recommendation is warranted until the company demonstrates a clear path to self-sustainability and positive cash flow in the second half of 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$4.50

High · most bullish analyst$7.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

The integration of Greenbrook clinics faces persistent operational hurdles, leading to higher-than-expected cash burn and operating expenses exceeding $105 million. Gross margins deteriorate further due to unfavorable service mix shifts and pricing pressure from competitors like BrainsWay. The company's cash reserves ($19.0 million as of Q1 2026) deplete rapidly, forcing highly dilutive equity raises or restrictive debt amendments under its Perceptive Advisors credit facility.

Base CaseCentral scenario

$1.5050%

Neuronetics achieves its full-year 2026 guidance, with revenue landing between $160 million and $166 million and gross margins stabilizing between 47% and 49%. Operating expenses are kept within the guided range of $100 million to $105 million. Operating cash flow remains negative at $13 million to $17 million, but improves to a flat-to-positive trajectory in the second half of 2026 as cost-saving initiatives take hold. The company maintains its market-leading position in TMS but continues to face valuation pressure due to ongoing net losses.

Bull CaseUpside scenario

$3.0030%

The integration of Greenbrook clinics accelerates rapidly, driving significant operational synergies and cost savings of $2.5 million to $3.0 million. Expanded insurance coverage, such as the Optum/UHC policy allowing Psychiatric Mental Health Nurse Practitioners (PMHNPs) to administer NeuroStar, unlocks access to millions of new lives. System shipments and treatment session utilization exceed expectations, pushing gross margins back toward the high-40s or low-50s and achieving positive operating cash flow ahead of schedule.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Market leadership in the non-invasive TMS depression treatment space with a massive installed base and the world's largest depression outcomes registry.
Vertical integration through the Greenbrook acquisition, capturing both device sales and high-value clinical service revenues.
Expanding payer coverage, notably the inclusion of PMHNPs by major insurers, which significantly broadens the addressable patient population.

Key Investment Risks

Severe gross margin dilution resulting from the lower-margin clinic services business model.
Persistent net losses and negative operating cash flow, with a limited cash runway of $19.0 million as of March 31, 2026.
Intense competition in the neuromodulation and depression therapy markets from both established medical device players and alternative pharmaceutical treatments.

Thesis Invalidation Triggers

Failure to achieve flat-to-positive operating cash flow trajectory in the second half of 2026.
GAAP gross margin dropping below 45% in consecutive quarters.
A breach of financial covenants under the amended Perceptive Advisors credit facility.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.